摘要
目的:研究卵巢癌组织中端粒酶活性、粘附分子CD44v5/v6的表达及其与卵巢癌恶性行为的关系。方法:TRAP-ELISA法半定量测定卵巢癌组织的端粒酶活性;FCM(Flowcytometry)技术分析DNA含量及粘附分子CD44v5/v6的阳性表达率。结果:①端粒酶活性随着卵巢癌临床分期、病理分级的升高而显著增高(P<0.05或0.01),淋巴结转移及DNA异倍体组端粒酶活性显著高于无转移及DNA二倍体组(P<0.05或0.01);②随着临床分期、病理分级的升高,粘附分子CD44v5/v6阳性表达率显著增加(P<0.01或0.05);淋巴结转移及DNA异倍体组CD44v5/v6阳性表达率明显高于无转移组及DNA二倍体组(P<0.01);③随着端粒酶活性增加,CD44v5/v6阳性表达率明显增高(P<0.01)。结论:肿瘤细胞增殖活性相关的端粒酶活性和肿瘤转移相关的CD44v5、v6都与卵巢癌的恶性程度及转移潜能密切相关,且二者之间存在相关性。联合检测可从不同的角度评价卵巢癌的恶性行为。
Objective： To investigate the relationship between the telomerase activity and expression of CD44 v5/v6 and the malignancy and metastasis potency of ovarian cancer. Methods： TRAPELISA was used to detect telomerase activity, and expression of CD44 v5/v6 and DNA content was analyzed by FCM （Flow eytometry）. Results： a） Telomerase activity increased significantly along with clinical stage （according to FIGO stage） and pathologic grade （P〈0.05 or P〈0.01 respectively）. It was significantly higher in patients with lymph node metastasis compared to those without the metastasis, and was significantly higher in patients with DNA aneuploid compared to those with DNA diploid （P〈0.05 or P〈0.01 respectively）, b） The expression of CD44 v5/v6 increased significantly along with clinical stage and pathologie grade （P〈0.05 or P〈0.01 respectively）. It was significantly higher in patients with lymph node metastasis or DNA aneuploid compared to those without metastasis （P〈0.01）. c） The expression of CD44 v5/v6 inereased significantly along with telomerase activity （P〈0.01）. Conclusion： Both the telomerase related with cell proliferation and CD44 v5/v6 in relation with tumor metastasis closely eorrelate with the malignaney and metastasis potency of ovarian cancer, and there is a close correlation between them. The malignant behavior of ovarian eancer through different aspects can be evaluated us- ing eombined detection.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2006年第9期481-484,共4页
Chinese Journal of Clinical Oncology
基金
江苏省自然科学基金资助(编号:BS2000069)
